|
|
 |
|
Viewing report
|
|
|
|
Commercial Insight: Antihypertensives - New Challenges for a Maturing Market
Datamonitor, Sep 2006, Pages: 206
We expect the antihypertensive market to exceed $40bn by 2015 across the seven major markets, with novel treatments and the market-leading ARBs delivering much of this value. However, significant hurdles exist, and pharmaceutical companies need to carefully design marketing campaigns and pricing structures for their products.
Scope of this title:
- Event-driven sales forecasts, for the period 2006-2015, for the US, Japan, France, Germany, Italy, Spain and the UK, plus a global overview
- Discussion of individual products in four main classes; beta blockers (BBs), CCBs, ACE inhibitors and the ARBs
- Profiles of the country and market specific issues which will impact future sales in the market including generic erosion and new product launches
- Commercial impact case studies on R&D innovation, clinical trial data and European healthcare reform
Highlights of this title:
- The growth rate of the antihypertensive market is declining. These changes reflect the challenges faced by pharmaceutical companies over the next decade, as brand erosion and healthcare reforms impact heavily. The slow and declining growth rate does not reflect a stationary market, but the battle between the drugs that make up the market
- Cozaars patent expiry in the US has the potential to alter the structure of the antihypertensive market dramatically. Threats of generic substitution and money-saving healthcare strategies which have plagued other markets are now approaching the successful ARB class, and will have an impact on the whole antihypertensive market.
- Large pharmaceutical companies that have established themselves in the cardiovascular arena are steering away from development in the antihypertensives market. While still continuing to enjoy large revenues from its cardiovascular arm, the research and development of Novartis shows that it is now investing elsewhere.
Reasons to order your copy:
- Quantify the future size and scope of the hypertension market and the potential for new products
- Analyze options to expand commercial potential through pursuit of new indications
- Formulate successful launch strategies to succeed in a highly competitive market
Customers who bought this item also bought
Forecast Insight: Antihypertensives - Key Patent Expiries Prevent Market Growth
Pipeline/Commercial Insight: Antihypertensives New class opportunity offset by key patent expiries
Forecast Insight: Antihypertensives New fixed dose combinations unable to stem the tide of patent expiries
The Pharmaceutical Market Outlook to 2018: Key Threats and Opportunities for Big Pharma and its Responses to them
Report on Antihypertensive Drug Market
Commercial Insight: Antidiabetics Patent expiries and cost containment initiatives balanced by pipeline products
Generic Cancer Market - New Legislation and a Wave of Patent Expiries to Transform the Market
Generic Series: Benchmarking Patent Expiries - Key Factors Affecting Brand Erosion At Patent Expiry
Commercial Insight: Migraine - Opportunities will Exist in the Wake of Generic Attack
Commercial Insight: Cytotoxic Therapy Cancer Brands - Looming Patent Expiries Limit Market Growth
Generic Series: An Introduction To The Canadian Generics Market - Key Trends And Leading Companies Shaping The Market
Cardiovascular Generic Drugs: Prospects and Opportunities to 2012
|
|
|
|
